Additionally, Necrostatin‐1 (Nec‐1), a RIPK1 inhibitor, drastically increased the survival of murine neuronal cells in vitro and promoted memory and learning retention as well as cognitive performance in AD models.8, 9 Nec‐1 treatment was further demonstrated to significantly diminish the level of Aβ oligomers, plaques and hyperphosphorylated tau.9 Here, MAPT is linked to Alzheimer disease.